RESEARCH TRIANGLE PARK – BioCryst Pharmaceutical’s stock offering has produced more than $63 million for the company.

BioCryst (Nasdaq: BCRX) said it sold all the 43.6 million shares offered, including 5.7 million to the underwriters of the offering.

“BioCryst expects to use the net proceeds of this offering for general corporate purposes, which may include, but are not limited to, worldwide development, manufacturing, regulatory and commercial activities” for its drug pipeline, the company said.

Durham-based Biocryst sells licensing rights to Japanese firm in $22M deal